By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


GlycoMimetics, Inc. 

14915 Broschart Road, Suite 200

Rockville   Maryland  20850  U.S.A.
Phone: 301-738-1166 Fax:




Company News
GlycoMimetics, Inc. (GLYC) Provides Update On Pfizer (PFE)’s Plans To Initiate Phase 3 Trial With Rivipansel In Mid-2015 4/7/2015 9:48:11 AM
GlycoMimetics, Inc. (GLYC) To Present First Preclinical Data On E-Selectin-CXCR4 Dual Antagonist For Cancer Indications At American Association for Cancer Research Annual Meeting 2015 3/19/2015 11:38:26 AM
GlycoMimetics, Inc. (GLYC) Reports Fourth Quarter And Year-End 2014 Results 3/17/2015 11:47:41 AM
GlycoMimetics, Inc. (GLYC) Announces Publication Of Phase 2 Data For Rivipansel In Sickle Cell Disease 3/3/2015 10:23:23 AM
GlycoMimetics, Inc. (GLYC) To Present At Two Investor Conferences In March 2/26/2015 12:14:06 PM
GlycoMimetics, Inc. (GLYC) To Present At 17th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference 2/3/2015 12:23:35 PM
GlycoMimetics, Inc. (GLYC) Highlights Potential Therapeutic Benefits Of Its Novel E-Selectin Antagonist At 56th American Society of Hematology Annual Meeting 12/9/2014 11:14:02 AM
University of Michigan To Study GlycoMimetics, Inc. (GLYC)’ GMI-1271 As Potential Treatment For Serious Blood-Clotting Disorder 12/4/2014 9:39:36 AM
GlycoMimetics, Inc. (GLYC) Announces Positive Top-Line Results From Phase 1 Study Of GMI-1271 In Healthy Volunteers 11/18/2014 1:00:39 PM
GlycoMimetics, Inc. (GLYC) To Present At Stifel Healthcare Conference 2014 11/12/2014 10:33:00 AM